Q1 Earnings Forecast for Immunic Issued By Leerink Partnrs

Immunic, Inc. (NASDAQ:IMUX) – Equities researchers at Leerink Partnrs issued their Q1 2026 earnings per share estimates for shares of Immunic in a report released on Thursday, August 7th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings of ($0.08) per share for the quarter. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Leerink Partnrs also issued estimates for Immunic’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.05) EPS.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02).

Several other research firms also recently commented on IMUX. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of Immunic in a report on Thursday, May 1st. B. Riley reiterated a “buy” rating and issued a $5.00 price objective (down from $6.00) on shares of Immunic in a report on Friday, May 23rd. William Blair reiterated an “outperform” rating on shares of Immunic in a report on Friday, May 16th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $10.00 price objective on shares of Immunic in a report on Friday. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $7.50.

Immunic Stock Performance

NASDAQ IMUX opened at $0.85 on Monday. Immunic has a one year low of $0.56 and a one year high of $2.11. The stock has a 50-day moving average of $0.85 and a 200 day moving average of $0.97. The company has a market capitalization of $83.75 million, a price-to-earnings ratio of -0.69 and a beta of 1.39.

Institutional Investors Weigh In On Immunic

A number of large investors have recently made changes to their positions in IMUX. Aberdeen Group plc grew its stake in shares of Immunic by 678.1% during the 2nd quarter. Aberdeen Group plc now owns 8,243,941 shares of the company’s stock valued at $5,750,000 after purchasing an additional 7,184,457 shares during the period. Millennium Management LLC grew its stake in shares of Immunic by 480.6% during the 4th quarter. Millennium Management LLC now owns 579,683 shares of the company’s stock valued at $580,000 after purchasing an additional 479,846 shares during the period. Focus Partners Wealth grew its stake in shares of Immunic by 19.1% during the 1st quarter. Focus Partners Wealth now owns 2,583,457 shares of the company’s stock valued at $2,816,000 after purchasing an additional 415,104 shares during the period. 683 Capital Management LLC grew its stake in shares of Immunic by 28.6% during the 1st quarter. 683 Capital Management LLC now owns 900,000 shares of the company’s stock valued at $981,000 after purchasing an additional 200,000 shares during the period. Finally, Renaissance Technologies LLC grew its stake in shares of Immunic by 45.6% during the 4th quarter. Renaissance Technologies LLC now owns 566,623 shares of the company’s stock valued at $567,000 after purchasing an additional 177,542 shares during the period. 51.82% of the stock is currently owned by institutional investors.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.